Childhood thyromegaly: recent developments.
Evaluation of a child with goiter includes historical review, physical examination, and measurement of serum concentrations of PBI, T4 and T3RU, TSH, and titers of antithyroglobulin and antithyroid microsomal antibodies. If there are no indications for more intensive evaluation such as history of cervical irradiation, a palpable abnormality of the thyroid gland or unusual laboratory findings (e.g., a significant PBI-thyroxine iodine discrepancy in the absence of a positive antithyroid antibody titer), a trial of TSH-suppressive therapy with thyroxine is undertake, even if the cause of thyromegaly has not been identified. If thyroid size diminishes in the ensuing six to 12 months, treatment is maintained for approximately two years and then discontinued. If the goiter recurs, or if there is impaired thyroid function, treatment is resumed. Periodically, antithyroid antibody titers and indices of thyroid function are determined. If the goiter does not diminish after a reasonable trial of suppressive therapy with adequate amounts of thyroxine (i.e., those quantities which will inhibit TRH-induced secretion of TSH), subtotal thyroidectomy is recommended to be certain that an underlying neoplasm has not been overlooked. A biopsy of the thyroid is not performed routinely in such children prior to operative therapy. Almost invariably, examination of the surgical specimen reveals CLT. Postoperatively, suppressive doses of thyroxine are maintained indefinitely. Inasmuch as thyroxine suppression of TSH secretion is essential in the management of patients with thyroid neoplasms, a limited medical trial, as described, does not place the patient at undue risk.
D000293:Adolescent; D002648:Child; D006111:Graves Disease / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D009381:Neoplasms, Radiation-Induced / Q000209:etiology; D011441:Propylthiouracil / Q000627:therapeutic use; D013854:Thioamides / Q000627:therapeutic use; D013959:Thyroid Diseases; D013961:Thyroid Gland / Q000276:immunology; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D013965:Thyroidectomy; D013967:Thyroiditis, Autoimmune / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D013974:Thyroxine / Q000627:therapeutic use
D007457:Iodine Radioisotopes; D013854:Thioamides; D011441:Propylthiouracil; D013974:Thyroxine